Hi Paolo and Rob, I’ve been experiencing similarly large CWRES (no “I”) values with NM7.4.1 for models which produced reasonable values when run unchanged in NM7.3. Other colleagues also saw this behavior. I believe we typically see it with bigger/more complex models (can’t recall a case where we had the problem with an analytical ADVAN).
Since computation of CWRES is parallelized since 7.4.1, so I guess something about the implementation may have been changed to enable this. I haven’t tried it myself, but if the “old” code is still used when the computation is not parallelized, one could speculate that disabling parallel evaluation of the residuals might help. The one thing I tried that did not help was using WRESCHOL. Kind Regards, Sven Von: [email protected] [mailto:[email protected]] Im Auftrag von Bauer, Robert Gesendet: Donnerstag, 16. November 2017 19:46 An: [email protected] Betreff: [NMusers] Extreme values of CWRESI in NONMEM 7.4.1? Paolo: I reviewed my NONMEM 7.4 testing results on CWRESI, and they provide the same values in NONMEM 7.3 as well as NONMEM 7.4. In case you ran the problem in parallel, because NONMEM 7.4 now executes the diagnostic evaluation in parallel as well, I tested under parallel execution conditions, and the CWRESI values are also the same between NONMEM 7.4 (parallel) and NONMEM 7.3. Incidentally, as a diagnostic that is expected to be normally distributed when the model is correct, CWRES is preferred even when INTERACTION is used in the $EST step. I would be happy to run your problem and see if I can detect something more subtle that is involved in your case. Robert J. Bauer, Ph.D. Senior Director Pharmacometrics R&D ICON Early Phase 820 W. Diamond Avenue Suite 100 Gaithersburg, MD 20878 Office: (215) 616-6428 Mobile: (925) 286-0769 [email protected]<mailto:[email protected]> www.iconplc.com<http://www.iconplc.com/> ICON plc made the following annotations. ------------------------------------------------------------------------------ This e-mail transmission may contain confidential or legally privileged information that is intended only for the individual or entity named in the e-mail address. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution, or reliance upon the contents of this e-mail is strictly prohibited. If you have received this e-mail transmission in error, please reply to the sender, so that ICON plc can arrange for proper delivery, and then please delete the message. Thank You, ICON plc South County Business Park Leopardstown Dublin 18 Ireland Registered number: 145835 ________________________________ Sitz der Gesellschaft: Wiesbaden - Registergericht: AG Wiesbaden HRA 9790 Persönlich haftende Gesellschafterin: AbbVie Komplementär GmbH Sitz der persönlich haftenden Gesellschafterin: Wiesbaden - Registergericht: AG Wiesbaden HRB 26371 Geschäftsführer: Dr. Patrick Horber, Thomas Scheidmeir, Dr. Stefan Simianer, William J. Chase Vorsitzende des Aufsichtsrats: Dr. Azita Saleki-Gerhardt This communication may contain information that is proprietary, confidential, or exempt from disclosure. If you are not the intended recipient, please note that any other dissemination, distribution, use or copying of this communication is strictly prohibited. Anyone who receives this message in error should notify the sender immediately by telephone or by return e-mail and delete it from his or her computer. Diese Kommunikation kann Informationen enthalten, die geheim, vertraulich oder hinsichtlich der Offenlegung beschränkt sind. Wenn Sie nicht der beabsichtigte Empfänger sind, nehmen Sie bitte zur Kenntnis, dass jede Weitergabe, Verteilung, Verwendung oder Vervielfältigung dieser. Kommunikation strikt untersagt ist. Jeder, der diese Nachricht fehlerhaft erhält, sollte den Sender unverzüglich telefonisch oder durch Rücksendung der E-Mail benachrichtigen und diese von seinem oder ihrem Computer löschen.
